BACKGROUND: Platelet activation is implicated in thrombotic disorders, but has not been described in acute clinical pulmonary embolism (PE). OBJECTIVES: To investigate the natural history of platelet activation in PE and associated markers of inflammation, thrombosis and cardiac dysfunction. METHODS: Thirty-five consecutive patients (age 62 +/-17 years) with acute PE were prospectively enrolled and followed for 6 months. Platelet activation was assessed by flow cytometry [measuring expression of platelet P-selectin, conformational activation of glycoprotein IIb/IIIa complex (PAC-1) and formation of platelet-leukocyte complexes] and by plasma soluble P-selectin. Platelet activation, right ventricular (RV) function (assessed as RV ejection area by transthoracic echocardiography), D-dimer and high-sensitivity C-reactive protein (hs-CRP) were measured at presentation and repeated over 6 months follow-up. RESULTS: Soluble P-selectin (56 +/-19 ng mL(-1), anovaP < 0.0001) and PAC-1 (1.5 +/- 1.8%, anovaP = 0.005) were mildly but significantly increased in patients with acute PE relative to healthy young men (soluble P-selectin 33 +/- 13 ng mL(-1), P < 0.001; PAC-1 binding 0.5 +/- 0.6%, P < 0.01) and age-matched controls (soluble P-selectin 31 +/- 9 ng mL(-1), P < 0.001; PAC-1 binding 0.4 +/-0.4%, P < 0.05). Platelet P-selectin expression and platelet-leukocyte complexes were not increased during acute PE. Echocardiographic RV ejection area correlated inversely with soluble P-selectin (r = -0.47, P = 0.007) and positively with platelet P-selectin (r = 0.49, P = 0.0007), suggesting P-selectin is shed from activated platelets in proportion to the severity of RV dysfunction. Elevated soluble P-selectin, D-dimer and hs-CRP demonstrated a time-dependent return to normal during 6 months follow-up. CONCLUSION: Platelet activation is evident after acute PE. Platelet activation correlates with the severity of RV dysfunction, and can persist for several months after acute PE.
BACKGROUND: Platelet activation is implicated in thrombotic disorders, but has not been described in acute clinical pulmonary embolism (PE). OBJECTIVES: To investigate the natural history of platelet activation in PE and associated markers of inflammation, thrombosis and cardiac dysfunction. METHODS: Thirty-five consecutive patients (age 62 +/-17 years) with acute PE were prospectively enrolled and followed for 6 months. Platelet activation was assessed by flow cytometry [measuring expression of platelet P-selectin, conformational activation of glycoprotein IIb/IIIa complex (PAC-1) and formation of platelet-leukocyte complexes] and by plasma soluble P-selectin. Platelet activation, right ventricular (RV) function (assessed as RV ejection area by transthoracic echocardiography), D-dimer and high-sensitivity C-reactive protein (hs-CRP) were measured at presentation and repeated over 6 months follow-up. RESULTS: Soluble P-selectin (56 +/-19 ng mL(-1), anovaP < 0.0001) and PAC-1 (1.5 +/- 1.8%, anovaP = 0.005) were mildly but significantly increased in patients with acute PE relative to healthy young men (soluble P-selectin 33 +/- 13 ng mL(-1), P < 0.001; PAC-1 binding 0.5 +/- 0.6%, P < 0.01) and age-matched controls (soluble P-selectin 31 +/- 9 ng mL(-1), P < 0.001; PAC-1 binding 0.4 +/-0.4%, P < 0.05). Platelet P-selectin expression and platelet-leukocyte complexes were not increased during acute PE. Echocardiographic RV ejection area correlated inversely with soluble P-selectin (r = -0.47, P = 0.007) and positively with platelet P-selectin (r = 0.49, P = 0.0007), suggesting P-selectin is shed from activated platelets in proportion to the severity of RV dysfunction. Elevated soluble P-selectin, D-dimer and hs-CRP demonstrated a time-dependent return to normal during 6 months follow-up. CONCLUSION: Platelet activation is evident after acute PE. Platelet activation correlates with the severity of RV dysfunction, and can persist for several months after acute PE.
Authors: Gabrielle J Pennings; Justine Siegwald; Andy S C Yong; Leonard Kritharides; Harry C Lowe Journal: J Thromb Thrombolysis Date: 2014-04 Impact factor: 2.300
Authors: Benjamin A T Rodriguez; Arunoday Bhan; Andrew Beswick; Peter C Elwood; Teemu J Niiranen; Veikko Salomaa; David-Alexandre Trégouët; Pierre-Emmanuel Morange; Mete Civelek; Yoav Ben-Shlomo; Thorsten Schlaeger; Ming-Huei Chen; Andrew D Johnson Journal: Am J Hum Genet Date: 2020-07-09 Impact factor: 11.025
Authors: Jeffrey A Kline; Michael A Puskarich; Jonathan W Pike; John Zagorski; Nathan J Alves Journal: Nitric Oxide Date: 2020-01-12 Impact factor: 4.427
Authors: George A Alba; Andriy O Samokhin; Rui-Sheng Wang; Ying-Yi Zhang; Bradley M Wertheim; Elena Arons; Edward A Greenfield; Martina H Lundberg Slingsby; Julia R Ceglowski; Kathleen J Haley; Frederick P Bowman; Yen-Rei Yu; John C Haney; George Eng; Richard N Mitchell; Anthony Sheets; Sara O Vargas; Sachiko Seo; Richard N Channick; Peter J Leary; Sudarshan Rajagopal; Joseph Loscalzo; Elisabeth M Battinelli; Bradley A Maron Journal: Am J Respir Crit Care Med Date: 2021-06-15 Impact factor: 21.405
Authors: Lauren E Gibson; Raffaele Di Fenza; Min Lang; Martin I Capriles; Matthew D Li; Jayashree Kalpathy-Cramer; Brent P Little; Pankaj Arora; Ariel L Mueller; Fumito Ichinose; Edward A Bittner; Lorenzo Berra; Marvin G Chang Journal: J Intensive Care Med Date: 2021-03-30 Impact factor: 3.510
Authors: Francisco Galeano-Valle; Lucía Ordieres-Ortega; Crhistian Mario Oblitas; Jorge Del-Toro-Cervera; Luis Alvarez-Sala-Walther; Pablo Demelo-Rodríguez Journal: Int J Mol Sci Date: 2021-03-05 Impact factor: 5.923